FDA approves Bone Cares Hectorol for treatment of kidney disease
Middleton, Wis. -- Bone Care International, Inc. announced Monday the U.S. Food and Drug Administration approved a new indication and strength for Hectorol
(doxercalciferol) Capsules. Hectorol, a pro-hormone vitamin D2 analog, is currently approved for the treatment of secondary hyperparathyroidi...
Bone Care marks solid quarter on Hectorol sales jump
Middleton, Wis. Bone Care International, Inc. , which makes the drug Hectorol, reported $2.5 million in profits on $22 million in sales for the quarter ended March 31.
Hectorol is a Vitamin D-based drug used to lower abnormally high levels of parathyroid hormone in patients with chronic kidn...
BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
...couraged to use Genzyme's Hectorol. While
Zemplar IV is the overwhelming market share leader in hemodialysis and
leads in every type of dialysis unit, hectorol
does its best in non-chains
and its worst in Davita. In CKD, Nephrologists continue to use oral
calcitriol most often. Compared to the prior year, RDs...
BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
... important PTH Modifier attributes are "Improves
Mortality", "Effectively Lowers PTH", "Supported by Clinical Data", and
"Well-Tolerated". Zemplar and hectorol
receive significantly higher ratings
than Amgen's Sensipar and Calcitriol on "Improves Mortality" and
"Well-Tolerated" whereas Sensipar receives signi...
BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
...ts and 40% of the Renal Dietitians feel that Abbott's
Zemplar and Genzyme's hectorol
are interchangeable, Zemplar claims an
advantage over hectorol
on the three PTH modifier attributes that
Nephrologists report as most impo...
BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
...04. While the majority of
nephrologists view Abbott's Zemplar and Genzyme's hectorol
interchangeable, Zemplar continues to grow its share in dialysis and CKD,
currently leading hectorol
in both markets. In dialysis patients, use of
Amgen's Sensipar has also inc...
Americas Third Coast nurtures biotechnology
Hectorol is given intravenously to dialysis patients. A capsule form of hectorol
is also available for peritoneal dialysis patients. Bone Care is waiting approval from the FDA for oral hectorol
to help patients with chronic kidney disease prior to dialysis. Mounting ev...
Wisconsin publicly traded biomedical companies report gains this quarter
... Due to new products and investments, the companies have been able to secure a foothold on the industry.
Bone Care: $1.2 million, boosted by doubled hectorol
Middleton-based pharmaceutical firm Bone Care International reported that for the third quarter in a row they have experienced a growth in p...
Plexus, Bone Care and Rockwell declare profitable first quarter
... Bone Care: $1.8 million, on doubled hectorol
Middleton, Wis. Bone Care International, which markets a vitamin... $1.8 million for the first quarter. The company said its sales of the drug hectorol
were $19.6 million, compared to $9.1 million for first-quarter 2004.
Massachusetts firm to buy UW spinoff Bone Care for $600 million
... Hectorol, into its stable of renal disease drugs. hectorol
treats secondary hyperparathyroidism in patients w...isease.
"We've been interested in Bone Care and hectorol
for quite a while," Quinn said. "Hectorol is very ...of its sales force since last year and the 0.5 mcg hectorol
capsule continues to gain share," First Albany sai...